TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28989150
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg, 5 mL) during general anesthesia induction, post-operative day 1 and day 2
Study: 28989150
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (5 mL) at corresponding time points
Study: 27101674
Drug: Budensonide nasal
Normalized name: budesonide Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budensonide nasal spray and desloratadine citrate disodium tablets for 4 weeks
Study: 23563958
Drug: nab-paclitaxel 150
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 150 mg/m(2)
Study: 23563958
Drug: nab-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 100 mg/m(2)
Study: 16093415
Drug: Constraint‐induced movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced movement therapy (CIMT)
Study: 20088415
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with Chinese herbal decoction plus western medicine (Group A)
Study: 20088415
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine alone (Group D)
Study: 11689273
Drug: Troglitazone 400
Normalized name: troglitazone 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone 400 mg per day
Study: 24261771
Drug: Celecoxib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (100 mg/dose, twice daily)
Study: 24261771
Drug: Loxoprofen (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxoprofen (60 mg/dose, 3 times daily)
Study: 21953376
Drug: gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gadobenate dimeglumine (intravenous contrast agent)
Study: 17155972
Drug: Apical periprostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical periprostatic block with 5 mL of 1% lidocaine
Study: 17155972
Drug: Basal periprostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal periprostatic block with 5 mL of 1% lidocaine
Study: 10401901
Drug: Morphine patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient-controlled analgesia with ketorolac
Study: 10401901
Drug: Morphine patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine patient-controlled analgesia without ketorolac (placebo)
Study: 2365458
Drug: Leish vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leish vaccine 5 or Leish vaccine 6 with or without Corynebacterium parvum
Study: 94089
Drug: No antithyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithyroid drugs before or when RAI was given
Study: 28387919
Drug: CRT-D with
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D with intensive drugs
Study: 97779
Drug: Single morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single morning dose of Loperamide
Study: 97779
Drug: Second bedtime
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second bedtime dose of Loperamide
Study: 21440713
Drug: High-power pain
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-power pain threshold ultrasound (HPPTUS) therapy
Study: 9648120
Drug: Caregiver information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver information about daily activities and performance ability
Study: 1092725
Drug: Stelazine (STEL)
DrugBank: Trifluoperazine (DB00831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stelazine (STEL) 50 mg/day
Study: 1092725
Drug: Loxapine (LOX)
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loxapine (LOX) 100 mg/day for four weeks
Study: 15233676
Drug: Tegaserod 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 12 mg b.i.d.
Study: 30268163
Drug: Oxygen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen plus conventional pain treatment
Study: 30268163
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen mixture plus conventional pain treatment
Study: 26753892
Drug: Imipramine 25
Normalized name: trimipramine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 25 mg once daily for 8 weeks
Study: 12399193
Drug: 50 micro
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micro g MPL/AlPO(4)
Study: 7655643
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (OCT) administration (300 to 600 micrograms/day for 6 months)
Study: 7655643
Drug: Octreotide (OCT)
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (OCT) administration
Study: 1097194
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg indapamide daily
Study: 1090415
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg frusemide daily
Study: 28732289
Drug: Emotion-focused supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emotion-focused supportive therapy
Study: 25641639
Drug: rhGH administration
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH administration (0.50 ± 0.06 mg/kg · wk) for 11.1 ± 4.8 months
Study: 17720777
Drug: Miglustat 100
Normalized name: miglustat 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglustat 100 mg without food
Study: 11704024
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with postoperative subconjunctival 5‐fluorouracil injections
Study: 11704024
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with one-layer conjunctiva-Tenon capsule closure
Study: 9059564
Drug: DHEA plus
Normalized name: Ascorbic Acid/Beta Sitosterol/Calcium Pantothenate/Dehydroepiandrosterone/Pentasterone/Pyridoxine 25 MG-700 MG-25 MG-6 MG Oral Tablet [DHEA PLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA plus insulin infusion
Study: 9059564
Drug: DHEA infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA infusion alone
Study: 22872648
Drug: PEG‐IFN first
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN first (180 μg/week for 24 weeks followed by LdT 600 mg/day for 24 weeks)
Study: 22872648
Drug: LdT first
Normalized name: LDT
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LdT first (600 mg/day for 24 weeks followed by PEG‐IFN 180 μg/week for 24 weeks)
Study: 21122961
Drug: 6‐times‐weekly in‐center
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐times‐weekly in‐center daily hemodialysis (1.5‐2.75 h/session)
Study: 8509578
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray 100 micrograms twice daily
Study: 7604951
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray 168 micrograms twice daily
Study: 17154747
Drug: Traditional Behavioral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional Behavioral Couple Therapy (TBCT)
Study: 11606830
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) - IV bolus dose of 15 mg/kg followed by a constant IV infusion of 10 mg/kg/hour until 12 hours after tourniquet deflation
Study: 8016790
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (100 micrograms/puff, two puffs three times daily for eight weeks)
Study: 18795264
Drug: Naltrexone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone treatment
Study: 24410736
Drug: Standard PD
Normalized name: PD-0299685
DrugBank: PD-0299685 (DB15264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PD solutions
Study: 22991015
Drug: Biocompatible PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biocompatible PD solutions
Study: 22696191
Drug: Local TCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local TCA injections
Study: 17585669
Drug: Jianying point-injection
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianying point-injection combined with massage
Study: 19226897
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture therapy
Study: 14998068
Drug: Naratriptan 2.5
Normalized name: naratriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 2.5 mg
Study: 3055454
Drug: Quinine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (10 mg/kg 3 times daily for 5 d)
Study: 24029535
Drug: Escitalopram 10-20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10-20 mg/day
Study: 19816208
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of PRBC at a rate of 1 mL/kg/h (Group A)
Study: 19816208
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of PRBC at a rate of 3 mL/kg/h (Group B)
Study: 11911755
Drug: Intravenous nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nitroglycerin
Study: 9462678
Drug: Standard-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose chemotherapy plus tamoxifen
Study: 9462678
Drug: Control (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (early stage breast cancer not treated with systemic therapy)
Study: 7993989
Drug: Oxcarbazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (600 mg) after overnight fasting
Study: 7993989
Drug: Oxcarbazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (600 mg) after a fat‐ and protein‐rich breakfast
Study: 31517876
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of standardized ashwagandha extract (Shoden) once daily
Study: 21153029
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg
Study: 21153029
Drug: Control (Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Aspirin 100 mg and Clopidogrel 75 mg)
Study: 17719472
Drug: Torasemide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide (10 to 20 mg/day)
Study: 17719472
Drug: Furosemide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (20 to 40 mg/day)
Study: 11281231
Drug: Higher plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher plasma renin activity in white children (7.1 +/- 3.6 ng/mL/h)
Study: 3737031
Drug: Aspirin-dipyridamole (990
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin-dipyridamole (990 mg/225 mg/day)
Study: 29682590
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose HBV vaccination (3 doses of 20μg) in healthy controls
Study: 24695091
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/day for 14 days
Study: 24695091
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) 4000 AxaIU (0.4 ml)/day for 14 days
Study: 18397549
Drug: Olanzapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (mean modal dose 12.0 mg/day, average duration 241 days)
Study: 18397549
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean modal dose 4.0 mg/day, average duration 86 days)
Study: 12437647
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori therapy
Study: 10692734
Drug: Omeprazole alone
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole alone followed by long-term famotidine 20 mg daily (Group B, n = 34)
Study: 6712754
Drug: Oral pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pulse methotrexate therapy (2.5-5.0 mg every 12 hours in 3 consecutive doses per week)
Study: 26421810
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg orally 2 hours before surgery and 24 hours after surgery)
Study: 21195195
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg)
Study: 22322110
Drug: +6D high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: +6D high water content daily disposable lens
Study: 22322110
Drug: -6D high
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: -6D high water content daily disposable lens
Study: 19948382
Drug: Buprenorphine-naloxone dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone dosing condition (19.7 mg for extreme pain, 15.0 mg for some pain, 12.8 mg for no pain)
Study: 19948382
Drug: Buprenorphine-naloxone dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone dosing condition
Study: 27930500
Drug: Prior treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior treatment regimen (SSRIs plus sodium valproate)
Study: 25911899
Drug: rebamipide 300
Normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: rebamipide 300 mg daily for 8 weeks plus rabeprazole 20 mg daily for the first 4 weeks (reb+PPI group)
Study: 25911899
Drug: rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg daily for 8 weeks (PPI group)
Study: 24703195
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg qd
Study: 24703195
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg qd
Study: 25191556
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (PJ) 500 ml
Study: 25191556
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink 500 ml
Study: 9489264
Drug: Task Force's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task Force's selection of criteria for identifying effective treatments
Study: 7616875
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of progesterone
Study: 7616875
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of progesterone
Study: 6820344
Drug: Verapamil (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (360 mg/die)
Study: 2139385
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg/die)
Study: 30900392
Drug: Fosaprepitant 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 3.0 mg/kg (up to 150 mg)
Study: 30900392
Drug: Fosaprepitant 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 1.2 mg/kg (up to 60 mg)
Study: 30900392
Drug: Fosaprepitant 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 0.4 mg/kg (up to 20 mg)
Study: 30900392
Drug: Fosaprepitant 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 5.0 mg/kg (up to 150 mg) in subjects under 12 years
Study: 17233426
Drug: Antidepressants for
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants for major depression
Study: 90354
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with adriamycin
Study: 90354
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy without adriamycin
Study: 31653260
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (attended twice weekly exercise and nutrition classes for 24 weeks)
Study: 31653260
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (attended didactic healthy lifestyle classes monthly)
Study: 15289215
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive strategy (medical therapy and coronary angiography at 4 to 48 hours)
Study: 31085788
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy
Study: 3310628
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g suspension four times daily for eight weeks)
Study: 26280662
Drug: Antioxidant-essential oil
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant-essential oil gel applied twice daily after brushing
Study: 14583134
Drug: 0.5% timolol/2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol/2.0% MK-507 combination b.i.d.
Study: 10760103
Drug: SB 290670
Normalized name: SB 224289
DrugBank: SB 224289 (DB17052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB 290670 (mixed endothelin A and B receptor antagonist)
Study: 8813984
Drug: Clindamycin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (1200 mg) via TVA-Bier
Study: 8813984
Drug: Gentamicin (284
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (284 mg) via TVA-Bier
Study: 8813984
Drug: Clindamycin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (1200 mg) via intravenous/intra-arterial injection
Study: 4015079
Drug: Intranasal HuIFN‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal HuIFN‐alpha 2 (1.25 X 10(6) IU)
Study: 24182419
Drug: Sumatriptan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (50 mg) plus promethazine (25 mg)
Study: 24182419
Drug: Sumatriptan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (50 mg) plus placebo
Study: 26062731
Drug: G-I (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-I (one session treatment of autologous haematopoietic stem cells)
Study: 26062731
Drug: G-II (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-II (two sessions treatment of autologous haematopoietic stem cells)
Study: 26062731
Drug: G-I (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-I (one session treatment)
Study: 26062731
Drug: G-II (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-II (two sessions treatment)
Study: 26062731
Drug: G-I and
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-I and G-II (both groups)
Study: 26062731
Drug: G-III (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-III (control group receiving regular liver treatment)
Study: 23184569
Drug: Spironolactone, 50
Normalized name: Spironolactone, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone, 50 mg once daily
Study: 23184569
Drug: Amiloride, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride, 10 mg once daily
Study: 16769348
Drug: Enteral recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral recombinant human G‐CSF (rhG‐CSF) for 5 days
Study: 3056473
Drug: Pre-treatment radiologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment radiologic reevaluation
Study: 28154462
Drug: Yunnan Baiyao
Normalized name: CAMPHOR (SYNTHETIC) 40.74 mg / MENTHOL 51.84 mg / METHYL SALICYLATE 117.998 mg TOPICAL PATCH [Yunnan Baiyao Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yunnan Baiyao (1000 mg orally every 12 h for 5 consecutive treatments)
Study: 26710696
Drug: Sensor augmented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor augmented insulin pump (SAP)
Study: 26710696
Drug: Double C
Normalized name: Capsaicin 0.05% Topical application Cream [DOUBLE CAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double C therapy (continuous subcutaneous insulin infusion and retrospective continuous glucose monitoring)
Study: 23433188
Drug: rh-APC infusion
Normalized name: Recombinant human activated protein C (rH-APC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh-APC infusion (24 mcg kg(‐1) h(‐1) for 96 h)
Study: 18783459
Drug: Provider Counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provider Counseling + Pharmacotherapy
Study: 12907900
Drug: Oral protein-bound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein-bound polysaccharide K plus 300 mg tegafur/uracil
Study: 12907900
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tegafur/uracil alone
Study: 10539814
Drug: Telmisartan 10
Normalized name: telmisartan 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 10 mg
Study: 26474943
Drug: Telmisartan 20
Normalized name: telmisartan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 20 mg
Study: 10539814
Drug: Telmisartan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (all doses)
Study: 31397288
Drug: CSLT (computerised
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSLT (computerised speech and language therapy) plus usual care
Study: 31397288
Drug: CSLT (computerised
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSLT (computerised speech and language therapy)
Study: 22134175
Drug: Methadone with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone with drug abuse counseling
Study: 19034342
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Mitomycin C instillation
Study: 10930147
Drug: Genotypic-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic-guided therapy (G4)
Study: 10930147
Drug: Genotypic-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypic-guided therapy (G3)
Study: 8452173
Drug: AMX/CP 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMX/CP 500 mg/125 mg three times a day
Study: 3785797
Drug: Topical 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-fluorouracil cream (5%, applied biweekly for at least six months)
Study: 3785797
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic 5-fluorouracil cream
Study: 28984095
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia and continuous wound infusion of anesthetics